New REVIVED data. More baseline HF symptoms than key HFrEF trials (eg DAPA-HF, PARADIGM-HF). KCCQ-OSS 62. Severe symptomatic HFrEF (despite NYHA II classification). Short term (not sustained) improvement in QoL (open label trial). JACC HF DOI: 10.1016/j.jchf.2024.03.010
Day 2 of #GTS 2024 starts in 90 minutes. All who register can view the best summary of 2023-24 trials for 12 months FOR FREE. Register at events.hubilo.com/global-trials-…. Day 2 is intervention, structural heart disease, EP, AF and hot trial updates.